Cargando…

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)

Detalles Bibliográficos
Autores principales:	Monschein, Tobias, Dekany, Sarinah, Zrzavy, Tobias, Ponleitner, Markus, Altmann, Patrick, Bsteh, Gabriel, Kornek, Barbara, Rommer, Paulus, Enzinger, Christian, Di Pauli, Franziska, Kraus, Jörg, Berger, Thomas, Leutmezer, Fritz, Guger, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344974/ https://www.ncbi.nlm.nih.gov/pubmed/37272963 http://dx.doi.org/10.1007/s00415-023-11784-1

Ejemplares similares

Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Feasibility of a smartphone app to monitor patient reported outcomes in multiple sclerosis: The haMSter interventional trial
por: Altmann, Patrick, et al.
Publicado: (2022)

The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study
por: Altmann, Patrick, et al.
Publicado: (2021)

Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
por: Altmann, Patrick, et al.
Publicado: (2021)

Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis
por: Monschein, Tobias, et al.
Publicado: (2020)

Remote visits for people with multiple sclerosis during the COVID-19 pandemic in Austria: The TELE MS randomized controlled trial
por: Altmann, Patrick, et al.
Publicado: (2022)

Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
por: Guger, Michael, et al.
Publicado: (2021)

COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020)

Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort
por: Schurz, Natascha, et al.
Publicado: (2021)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis
por: Krajnc, Nik, et al.
Publicado: (2022)

Exome-Sequence Analyses of Four Multi-Incident Multiple Sclerosis Families
por: Zrzavy, Tobias, et al.
Publicado: (2020)

Real‐life use of oral disease‐modifying treatments in Austria
por: Guger, Michael, et al.
Publicado: (2019)

Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria
por: Guger, Michael, et al.
Publicado: (2023)

Impact of vaccination on COVID‐19 outcome in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2023)

Serum neurofilament light chain withstands delayed freezing and repeated thawing
por: Altmann, Patrick, et al.
Publicado: (2020)

Oral therapies for treatment of relapsing–remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method
por: Guger, Michael, et al.
Publicado: (2020)

Author Correction: Seven day pre-analytical stability of serum and plasma neurofilament light chain
por: Altmann, Patrick, et al.
Publicado: (2022)

Seven day pre-analytical stability of serum and plasma neurofilament light chain
por: Altmann, Patrick, et al.
Publicado: (2021)

Immunosenescence in Neurological Diseases—Is There Enough Evidence?
por: Rommer, Paulus S, et al.
Publicado: (2022)

No Association of Multiple Sclerosis with C9orf72 Hexanucleotide Repeat Size in an Austrian Cohort
por: König, Theresa, et al.
Publicado: (2023)

Has the pandemic changed treatment strategy in multiple sclerosis?
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Long‐term outcome after COVID‐19 infection in multiple sclerosis: A nation‐wide multicenter matched‐control study
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Clinical scales in autoimmune encephalitis—A retrospective monocentric cohort study
por: Macher, Stefan, et al.
Publicado: (2023)

Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
por: Krajnc, Nik, et al.
Publicado: (2022)

Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 1: Empfehlungen
por: Monschein, Tobias, et al.
Publicado: (2021)

Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: Impfstofftechnologien
por: Monschein, Tobias, et al.
Publicado: (2021)

Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria
por: Guger, Michael, et al.
Publicado: (2023)

Longitudinal measurement of cerebrospinal fluid neurofilament light in anti‐N‐methyl‐D‐aspartate receptor encephalitis
por: Macher, Stefan, et al.
Publicado: (2020)

Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Individual Perception of Telehealth: Validation of a German Translation of the Telemedicine Perception Questionnaire and a Derived Short Version
por: Altmann, Patrick, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4bf0g23vpf1r4u4c6eu9gm9du2